Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2001
01/31/2001CN1281697A Multifunctional medicine
01/31/2001CN1281696A Oral liquor for curing duodenal ulcer
01/31/2001CN1061351C Intermediates diaza or oxadiazabicyclic compounds
01/31/2001CN1061350C 2.7-substituted octahydro-pyrrolo (1.2-A) pyrazine derivatives
01/31/2001CN1061348C New crystal modification of quinolinecarboxylic acid hydrochloride, process for its preparation and pharmaceutical formulations
01/31/2001CN1061347C 抗真菌剂 Antifungal agents
01/31/2001CN1061346C Diazabicycloalkene derivatives and use, and drug composition containing said derivatives
01/31/2001CN1061341C 1-amino-ethylindole-derivatives
01/31/2001CN1061339C Novel sulfonamide inhibitors of aspartyl protease
01/31/2001CN1061256C External-use blood pressure reducing ointment
01/31/2001CN1061248C Powder agent formula for curing acne and seborrhea and production method
01/31/2001CN1061236C Ointment for curing eczema
01/31/2001CN1061231C Preparing method for cataract eye drops and cataract eye drops prepared by said method
01/31/2001CN1061213C Method for combating fish parasites
01/30/2001US6180824 Alpha-alkyl-s-alkyl-homocysteine sulfoximines wherein alpha-alkyl contains 2 to 8 carbon atoms and s-alkyl contains 1 to 10 carbon atoms except for alpha-ethyl-methionine sulfoximine
01/30/2001US6180816 Anti-viral compounds
01/30/2001US6180815 Compounds which abrogate hemagglutinin-mediated fusion of virus-host membranes; treating influenza
01/30/2001US6180805 Photochemical process for the production of previtamin D3
01/30/2001US6180803 Steroid drugs
01/30/2001US6180793 Process for the preparation of a pharmacologically active substance
01/30/2001US6180792 Drugs, antisecretory agents and hormone inhibitors for lh-rh
01/30/2001US6180791 Synthesis of 8-substituted xanthines
01/30/2001US6180787 Process for preparing o-(3-amino-2-hydroxy-propyl)-hydroxymic acid halides
01/30/2001US6180786 Antagonist for excitory amino acids
01/30/2001US6180782 Preparation of clavulanate salts
01/30/2001US6180781 Process for making mometasone furoate monohydrate
01/30/2001US6180780 Processes for preparation of 9,11-epoxy steroids and intermediates useful therein
01/30/2001US6180773 The cc type chemokines belong to a family of polypeptides which have proven to be mediators of immune reactions, and which have antiviral activity with respect to hiv
01/30/2001US6180766 Nucleosides and oligonucleotides containing boron clusters
01/30/2001US6180687 In situ repairing detached retinal tissue
01/30/2001US6180682 Buccal drug delivery system for use in male contraception
01/30/2001US6180681 2-cyclopenten-1-one as an inducer of HSP70
01/30/2001US6180680 Cardiovascular disorders
01/30/2001US6180679 Parasiticide
01/30/2001US6180678 Use of adrafinil to treat behavioral problems in aged canines
01/30/2001US6180677 Tyrosine-derived compounds as calcium channel antagonists
01/30/2001US6180676 Guanylhydrazones and their use to treat inflammatory conditions
01/30/2001US6180675 IL-8 receptor antagonists
01/30/2001US6180674 Therapy for skin disorders
01/30/2001US6180673 Corneal subepithelial opacity (haze) inhibitor
01/30/2001US6180671 Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
01/30/2001US6180669 Method for treatment of dermatological disorders
01/30/2001US6180667 Esters of acyl L-carnitines and pharmaceutical compositions containing same for treating endotoxic shock
01/30/2001US6180666 Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
01/30/2001US6180665 Crystalline polymorphic form of (S,S,S)-N-(1-[2-carboxy-3 (N2-mesyllyslamino) propyl]-1- cyclopentylcarbonyl) tyrosine
01/30/2001US6180664 Pentaerythritol derivatives, their production and use and intermediates for their synthesis
01/30/2001US6180662 Mixture of cinnamic acid, antioxidant, enzyme, microbiocides and viricides
01/30/2001US6180660 Cholesterol-lowering therapy
01/30/2001US6180659 Using a dibenzo(b,f)-(oxepin or thiepin) compound
01/30/2001US6180658 Method for counteracting blood platelet aggregation in a patient in need thereof
01/30/2001US6180657 Melatonin derivatives for use in treating desynchronization disorders
01/30/2001US6180656 Use of condensated (hetaryl-substituted) 1-benzal-3-pyrazol derivates for treating special diseases of the cardiovascular and the central nervous systems
01/30/2001US6180654 Heterocyclic nonnucleoside inhibitors of reverse transcriptase
01/30/2001US6180651 Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
01/30/2001US6180650 Antiinflammatory agents; respiratory system disorders; skin disorders; antitumor agents
01/30/2001US6180648 Analogs of cocaine
01/30/2001US6180647 Gastrointestinal disorders; nervous system disorders
01/30/2001US6180646 Retroviral protease inhibitors
01/30/2001US6180645 Antiepilepic agent
01/30/2001US6180644 Immunotherapeutic agents
01/30/2001US6180643 Antagonist of interleukins, tumor necrosis factor
01/30/2001US6180639 Therapy for human immunodeficiency virus
01/30/2001US6180637 Therapy for parkinson, alzheimer disease
01/30/2001US6180636 Substituted pyrrolopyrimidines and processes for their preparation
01/30/2001US6180635 Novel thieno(2,3-d)pyrimidinediones which exhibit pharmacological activity, in particular immunosuppressive activity; treating allograft rejection
01/30/2001US6180634 Combination therapy for the treatment of AIDS
01/30/2001US6180633 Drug resistance and multidrug resistance modulators
01/30/2001US6180632 Use of these compounds for treating disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or t cell activation and proliferation
01/30/2001US6180631 Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds
01/30/2001US6180630 Tricyclic pyrazolo-pyridazinone analogues as GAGA-A receptor ligands
01/30/2001US6180628 Compounds, compositions and methods for treating influenza
01/30/2001US6180627 Antithrombotic agents
01/30/2001US6180626 Oxaspirooctane derivatives to prevent retention of carcinomatous pleural effusion or carcinomatous ascites
01/30/2001US6180625 Modulating and normalizing an impaired haemostatic balance in a mammal, which method comprises administering an effective amount of novel benzoxazin derivatives; anticoagulants
01/30/2001US6180624 Tachykinin antagonist and an opioid analgesic effective at treating pain or nociception
01/30/2001US6180623 Used as analgesics and anti-pruritic agents
01/30/2001US6180621 Administering to warm-blooded animals for treatment and prevention of infectious diseases caused by helicobacter pylori
01/30/2001US6180620 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
01/30/2001US6180619 Prenyl transferase inhibitors
01/30/2001US6180618 Propanolamine derivatives linked to bile acids, processes for their preparation, pharmaceuticals comprising these compounds, and their use
01/30/2001US6180617 Method for reducing absorption of undesired lipids in the gastrointestinal tract
01/30/2001US6180616 Use of purine receptor agonists to alleviate or normalize physiopathologically excited sensory nerve function
01/30/2001US6180615 Propargyl phenyl ether A2A receptor agonists
01/30/2001US6180611 Inhibitors of matrix metalloproteinases and tumor necrosis factor
01/30/2001US6180599 May include lectins and/or fluoride in addition to medium-chain fatty acids; toothpaste, spray, gum
01/30/2001US6180597 Useful in treating or preventing conditions such as pulmonary hypertension, ischemic stroke, impotence, heart failure, hypoxia-induced conditions, insulin deficiency, progressive renal disease, gastric or esophageal motility syndrome, etc.
01/30/2001US6180577 Anti-germ attachment—composition
01/30/2001US6180403 Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression
01/30/2001US6180402 Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor
01/30/2001US6180387 Nucleotide sequence coding an enzymatic polypeptide; for the detection of bactericides and batericidal agonist and antagonists which prevent bacterial infection
01/30/2001US6180384 Compounds
01/30/2001US6180362 Peptides which inhibit ras protein activity, their preparation and use
01/30/2001US6180356 Membrane pore inhibiting agents for treating infection
01/30/2001US6180355 Method for diagnosing and treating chronic pelvic pain syndrome
01/30/2001US6180353 Nucleotide sequences associated with suppression of transcription binding protein associated with apoptosis; for the treatment and prevention defects associated with apoptosis
01/30/2001US6180142 Reduction of surfactant inactivation in pulmonary surfactant therapy
01/30/2001US6180141 Composite gel microparticles as active principle carriers
01/30/2001US6180140 Modified amino acids for drug delivery
01/30/2001US6180139 Composition and method for treating nonalcoholic steatohepatitis
01/30/2001US6180136 Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use